Abstract #1322

SHINKEI Quant: Simultaneous Acquisition of MR Neurography and T2 Mapping for Quantitative Evaluation of Chronic Inflammatory Demyelinating Polyneuropathy

Masami Yoneyama¹, Osamu Togao², Akio Hiwatashi², Yuriko Ozawa³, Makoto Obara¹, Tomoyuki Okuaki⁴, and Marc Van Cauteren⁴

¹Philips Electronics Japan, Tokyo, Japan, ²Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ³Yaesu Clinic, Tokyo, Japan, ⁴Philips Healthcare Asia Pacific, Tokyo, Japan

MR neurography achieves selective depiction of peripheral nerves and detects pathological changes related to neuropathies as a signal abnormality. Recently, we proposed a novel MR neurography sequence (SHINKEI) that provides high-quality MR neurography in the brachial plexus and the lumbosacral plexus. However, SHINKEI could not quantitatively assess the nerve pathology. In this study, we developed a new sequence (SHINKEI-Quant) to simultaneously acquire MR neurography and T₂ mapping by further optimizing the iMSDE preparation. SHINKEI-Quant could simultaneously provide both MR neurography and T₂ maps without prolongation of acquisition time compared with the conventional SHINKEI sequence. This quantitative sequence may be helpful to quantitatively assess the nerve pathology such as chronic inflammatory demyelinating polyneuropathy.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.